Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 2, week 4, week 6, and week 8
Awards & highlights
No Placebo-Only Group
Summary
This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.
Eligible Conditions
- Inflammatory Diseases
- Rheumatoid Arthritis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, week 2, week 4, week 6, and week 8
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 2, week 4, week 6, and week 8
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in inflammatory markers from Baseline to Week 8
Secondary study objectives
Change in self-reported symptoms and quality of life from Baseline to Week 8
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CBG TreatmentExperimental Treatment1 Intervention
Participants will receive 0.5 milliliters of purified cannabigerol (CBG) in sesame oil once daily in the evening for a duration of eight weeks.
Find a Location
Who is running the clinical trial?
Raphael PharmaLead Sponsor
CitruslabsIndustry Sponsor
89 Previous Clinical Trials
4,718 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger